Fundraising FoxPivotal Life Sciences
Crossover fundSan Francisco · Pre-Seed–Late Stage · 15 people tracked
Also known as Pivotal bioVenture Partners · Pivotal bioVenture Partners CNS SLP · PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC · Pivotal bioVenture Partners SLP
Find your way into Pivotal Life Sciences
Each arrow is one introduction. Sign up to fill in the first one.
Ask Pascal Levensohn to introduce you to AJ Velasquez-Mao
You →Pascal · together at Dolby Family Ventures →AJ
Ask Jamie Chen to introduce you to Benjamin Li
You →Jamie · together at Lucy Therapeutics →Benjamin
Ask Sam Okafor to introduce you to Ash Khanna
You →Sam · together at Tentarix →Ash
- Jeni Lee266 people can intro you
- Peter Bisgaard207 people can intro you
- Glenn Batchelder202 people can intro you
Sign up to find every way you can get introduced to Pivotal Life Sciences
- Your email: who you already know at Pivotal Life Sciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Pivotal Life Sciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Pivotal Life Sciences invests across the life sciences ecosystem through three strategies. Pivotal bioVenture Partners, established in 2017, is a venture capital arm backing transformative therapeutic-focused healthcare companies in North America and Europe. Pivotal bioVenture Partners China concentrates on venture building in the life sciences industry, partnering with innovative healthcare companies in the Greater China region. Pivotal Public Equity targets investment opportunities in publicly traded life sciences companies seeking to scale and grow. The firm's overall focus is supporting the development of high-impact therapeutics that address significant unmet medical needs on a global basis.
Source: firm website, verified Sep 29, 2026.
Team · 15 people
from the firm's website & public directories
Founder mafia
2 people who came through Pivotal Life Sciences went on to found or lead other companies.
What they invest in
from 40 of 49 portfolio companiesBiotech ×35Healthtech ×25Medical Devices ×13AI & Machine Learning ×6Digital Health ×5Deep Tech ×4Consumer ×1Data & Infrastructure ×1
HQs:United States×26Azerbaijan×1Switzerland×1China×1
Who they back
founder profiles across 21 portfolio companiesFounding team size:solo founder×122 founders×53 founders×34+ founders×1
What their founders studiedfrom 12 founders with field-of-study data
Business & Management ×3Life Sciences ×3Medicine ×3
Where their founders worked beforefrom 17 founders with career history
Receptos ×3Brigham and Women's Hospital ×2Harvard Medical School ×2Johnson & Johnson ×2
Investments · 49 tracked
founders shown can be your intro pathBy year:2025 · 32024 · 22023 · 22022 · 12021 · 12020 · 32019 · 42018 · 218 dated
Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases, with a lead program in RLYB116, a C5 complement inhibitor in clinical development, and a preclinical program in RLYB332, a matriptase-2 antibody for iron overload disorders.
HealthtechFarmington, US
Jeffrey M. Fryer(Executive Officer, Director)Martin W. Mackay(Executive Officer, Director)Stephen Uden(Executive Officer, Director)
Board seatRob Hopfner· per SEC Form D
Co-investors5AM VenturesCanaan Partners
Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.
BiotechDeep TechHealthtechSouth San Francisco, US
Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Grant E. Pickering(Chief Executive Officer)Ashish Khanna(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)
Board seatRob Hopfner· per SEC Form D
Co-investorsAbingworthCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesJanus Henderson InvestorsLongitude Capital+4 more
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+9 more
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesIA Seed VenturesLongitude CapitalOrbiMed+19 more
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsPfizer Venture InvestmentsRA CapitalSamsara BioCapitalSofinnova VenturesVivo CapitalNan Fung Life Sciences+3 more
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Co-investorsARCH Venture PartnersBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Samsara BioCapital+3 more
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inJosh Ofman(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)in
Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu Ventures+13 more
-2.png)
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)inJeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
BoardAaron Royston(Director)in
Co-investorsAisling CapitalHBM Healthcare InvestmentsHBM PartnersParagon Biosciences LLCValor Equity PartnersvenBio Partners+3 more
Immunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer.
BiotechHealthtechExton, US
Scott K. Dessain(Executive Officer, Director)inDennis H Giesing(Executive Officer)inCorleen Roche(Executive Officer)inMichael J Morin(Executive Officer)Purnanand Sarma(Executive Officer, Director)inGeorge Hobbs(Executive Officer)
Co-investorsBioAdvanceDelaware Crossing Investor GroupEvolution VC PartnersMilitia Hill VenturesRobin Hood VenturesT. Rowe Price
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)inLauren Stipp(Executive Officer)Mark Panoff(Executive Officer)Heather Turner(President & Chief Executive Officer and Director)Gad Soffer(Chief Operating and Business Officer)Anna Eramo(Chief Medical Officer)
Co-investorsPontifax Venture CapitalTarnagulla VenturesVida VenturesTCG Crossover
MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease.
BiotechRedwood City, US
Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)Erin Foff(Executive Officer)inJames Lillie(Executive Officer)Jonathan Gillis(Executive Officer)inVishwas Setia(Executive Officer)in
Co-investorsAvego BioScience CapitalForbionNovo Holdings
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)+9 more
.png)
Rallybio is a clinical-stage biotech company developing therapies for people with severe and rare diseases, with a pipeline focused on complement dysregulation and hematology.
BiotechHealthtechNew Haven, US
Stephen Uden(Founder)inMartin W. Mackay(Chairman of the Board of Directors)inJon(Chief Financial Officer)
Co-investors5AM VenturesCanaan PartnersConnecticut InnovationsF-Prime CapitalMitsui Global InvestmentSolasta Ventures+1 more
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc.
BiotechHealthtechNew Haven, US
Thomas Sciascia(Executive Officer)Jennifer Good(Co-Founder, President and CEO)inThomas Sciascia, M.D.(Co-Founder, Chief Scientific Officer)Lisa Delfini(Executive Officer)inWilliam Forbes(Executive Officer)inMichael Heffernan(Director)in
Co-investorsAPERTURE Venture PartnersFrazier Life SciencesNew Enterprise Associates (NEA)Omega Funds
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)inEmily M. Leproust(Chief Executive Officer and Chair of the Board)inEmily Leproust, PhD(CEO and Co-Founder of Twist)Patrick Finn(President and Chief Operating Officer)in
Co-investors+ND Capital3E Bioventures CapitalARCH Venture PartnersAsset Management CompanyATEL VenturesBay City Capital+10 more
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Grant Pickering(Founder)inGrant E. Pickering(Chief Executive Officer and Director)in
Co-investorsBioRock VenturesCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesLongitude CapitalRA Capital+3 more
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Co-investorsDelos CapitalLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersQuan CapitalSR One Capital Management+2 more
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersRiverVest Venture PartnersYsios Capitalabrdn plc+4 more
Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.
BiotechHealthtechMedical DevicesSuzhou, CN
Co-investorsLAVLilly Asia VenturesOrbiMedExome Asset ManagementJanus Henderson InvestorsRA Capital+2 more
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoinMichael Martin(President, Chief Executive Officer)inStephen Mullennix(Executive Officer)in
BoardSerge Messerlian(Director)inCariad Chester(Director)in
Board seatRob Hopfner· per SEC Form D
Co-investorsaMoonCRV (Charles River Ventures)DCVC (Data Collective)M VenturesNeotribe VenturesSoftBank Vision Fund+3 more
Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team.
BiotechHealthtechSouth San Francisco, US
Kathleen Collins(Director)inLawrence Kong(Executive Officer)inRon Park(President & CEO)inFrancine Gregoire(Chief Scientific Officer)inPriya Parameswaran(Chief Business Officer)in
BoardJayson Punwani(Director)in
Co-investorsBEVCSR One Capital ManagementAbingworthOsage University Partners
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Co-investors5AM VenturesEcoR1 CapitalNew Enterprise Associates (NEA)RA CapitalSofinnova VenturesCowen Healthcare Investments+2 more
Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.
BiotechHealthtechSouth San Francisco, US
Leonid Beigelman(President)inLawrence M. Blatt(Chairman, President & CEO (Co-founder))inHardean Achneck(Executive Officer)inBrian Dowd(Executive Vice President - Controller)inLucinda Quan(Executive Vice President - General Counsel)inJulian Symons(Executive Vice President, Chief Scientific Officer)in
Co-investorsRoche Venture FundMPM BioVentures 2014Vivo Capital
HealthtechSaratoga Springs, US
Daniel T. Pickett III(Executive Officer, Director)Timothy Koehler(Executive Officer)Greg Stephen(Executive Officer)
BoardHolly Benson(Director)Mary Langowski(Director)Peter Dorsman(Director)
Co-investorsClaritas CapitalWhat If VenturesOlive Tree VenturesTakeda VenturesVista Equity Partners
Ark provides a customizable digital platform for venture capital and private equity firms to manage investor communications, performance reporting, and document sharing with their limited partners.
Enterprise SoftwareFintechSaaS
Co-investorsAcies InvestmentsAloft VCAlta PartnersAmity VenturesArtis VenturesAsymmetric Capital Partners+21 more
Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.
ConsumerGamingBaku, AZ
Co-investorsAtlas VentureMission BiocapitalPfizer Venture InvestmentsPfizer Ventures
DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
BiotechDigital HealthMedical DevicesBoston, US
Robert Brucker(Executive Officer)inKarl R. Beutner(Executive Officer, Director)inNichola Eliovits(Executive Officer, Director)inMax Dawson(Executive Officer)in
BoardWilder Ramsey(Director)inJennifer Lee(Director)
Co-investorsCivilization Ventures Management, LlcJoyance PartnersOlive Tree CapitalStart CapitalToba CapitalValia Ventures+1 more
Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.
BiotechHealthtechPalo Alto, US
Luis Pena(President & Chief Executive Officer)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Co-investorsAndera PartnersAvego BioScience CapitalB Capital GroupB4 CapitalBeiersdorf Innovation FundFemHealth Ventures+3 more
.jpeg){kind=logo}
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.
BiotechHealthtech
John Valliant(Founder)in
Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCapLumira VenturesSeroba Life SciencesVenture OntarioYsios Capital+6 more
HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.
AI & Machine LearningBiotechHealthtech
BoardBruce Booth(Chairman)in
Co-investorsAtlas VentureB Capital GroupB4 CapitalMRL Ventures FundSofinnova PartnersSolasta Ventures+2 more
BiotechBoston, US
Axel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)
BoardEdward Mathers(Director)Rob Hopfner(Director)inMartin Edwards(Director)
Co-investorsLongitude CapitalNew Enterprise Associates (NEA)Sanofi VenturesSofinnova Ventures
IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
BiotechMedical Devices
Dr. Dhingra
Co-investorsAvoro Capital AdvisorsEIR VenturesKurma PartnersRA CapitalSamsara BioCapitalSunstone Capital+3 more
Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.
Co-investorsARCH Venture PartnersSofinnova VenturesAlexandriaPureTech HealthWellcome Trust
Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep.
BiotechDigital HealthHealthtechMedical Devices
Barbara(Regulatory Affairs & Quality Assurance leadership)Kevin(Pharmaceutical Development leadership)Pranav(Head of Finance & Operations)Ben(Executive / Board)
BoardDavid White(Sleep Medicine Advisor)
Co-investorsBroadview VenturesNorwest Venture PartnersSupermoon CapitalHTGFInkef
Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments.
BiotechHealthtechMedical DevicesBoston, CH
Riad Sherif(Chief Executive Officer)in
Co-investorsBay City CapitalBrunnur Ventures GPVI PartnersBVCF
San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.
BiotechSan Diego, US
David S. Mullarkey(Executive Officer, Director)Arnold Oliphant(Executive Officer)inKen Song, M.D., Ph.D.(Executive Officer, Director)Kelly Perez(Executive Officer)John Murphy, Ph.D.(Executive Officer)Millard Y Chan(Chief Operating Officer, Secretary and Director)
Co-investorsARCH Venture PartnersATEL VenturesDCVC (Data Collective)Decheng CapitalLam CapitalALTITUDE LIFE SCIENCE VENTURES+3 more
This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms.
Biotech
Co-investorsCDP Venture CapitalIreland Strategic Investment FundAdams Street PartnersGenesys CapitalHealthCapOrbiMed+1 more
Vericel manufactures and markets advanced cell therapy products for sports medicine and severe burn care, and holds an exclusive North American license for NexoBrid.
BiotechHealthtechMedical Devices
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Co-investorsAtlas VentureLightstone VenturesVida VenturesHatteras Venture PartnersLongwood Fund
Windward delivers AI-powered operational intelligence for maritime security and commercial applications, fusing behavioral analytics and multi-sensor data to detect threats and opportunities.
AI & Machine LearningData & InfrastructureDefense TechTel Aviv
Amiad Daniel(Executive Officer, Director)Matan Peled(Director)in
BoardDov Gatmon(Director)Patrick Poon(Director)Eden Shochat(Director)inThompson Hutton(Director)in
Co-investorsAlephFTV CapitalThompson Hutton, LLCJanus Henderson InvestorsQiming Venture PartnersQuan Capital+3 more
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.
BiotechHealthtech
Co-investorsOrbiMedQuan CapitalRA CapitalSanofi VenturesSR One Capital ManagementJanus Henderson Investors+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Alkahest, A Grifols CompanyAnthos TherapeuticsArcutis BiotherapeuticsCybinExscientiaInozymeLucy TherapeuticsObsidian Therapeutics
Exits · 21
17 IPOs · 4 acquisitions · showing 19Rallybio HoldingsNASDAQ: RLYBSUTROVAX, INC.NASDAQ: PCVXAvalyn Pharma IncNASDAQ: AVLNBioAge LabsNASDAQ: BIOABolt BiotherapeuticsNASDAQ: BOLTGossamer BioNASDAQ: GOSSGrailNASDAQ: GRALHarmony BiosciencesNASDAQ: HRMYImmunomeNASDAQ: IMNMLB PharmaceuticalsNASDAQ: LBRXMapLight TherapeuticsNASDAQ: MPLTParabilis MedicinesNASDAQ: PBLSRallybio, LLCNASDAQ: RLYBTrevi TherapeuticsNASDAQ: TRVITwist BioscienceNASDAQ: TWSTVaxcyteNASDAQ: PCVXZenas BiopharmaNASDAQ: ZBIOInozymeacq. by BioMarin Pharmaceutical Inc.Vigil Neuroscienceacq. by Sanofi
Portfolio news
latest coverage across their companiesImmunome · stocktitan.net · Aug 14, 2026
Trevi Therapeutics · simplywall.st · Aug 1, 2026
Vericel · finance.yahoo.com · Jul 30, 2026
Windward Bio · finsmes.com · May 5, 2026
Addition Therapeutics · finsmes.com · Dec 17, 2025
Mosanna · finsmes.com · Jun 9, 2025
IPO stake values · per SEC filings · 5
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Bolt Biotherapeutics | 5.5% | $20.00 | Feb 2021 | $37.8M |
| SUTROVAX, INC. | 4.4% | $16.00 | Jun 2020 | $34.1M |
| Vaxcyte | 4.4% | $16.00 | Jun 2020 | $34.1M |
| Rallybio, LLC | 5.4% | $13.00 | Jul 2021 | $22M |
| Rallybio Holdings | 5.4% | $13.00 | Jul 2021 | $22M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Pivotal Life Sciences made?
- Pivotal Life Sciences has 49 tracked investments, 21 of which have exited, including 3 dated in the last 24 months.
- What stage does Pivotal Life Sciences invest at?
- Pivotal Life Sciences invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Pivotal Life Sciences focus on?
- Pivotal Life Sciences focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Pivotal Life Sciences located?
- Pivotal Life Sciences is headquartered in San Francisco, US.
- Does Pivotal Life Sciences lead rounds?
- Pivotal Life Sciences typically participates in rounds rather than leading them.
- Who does Pivotal Life Sciences co-invest with?
- Pivotal Life Sciences most often shares deals with RA Capital, ARCH Venture Partners, New Enterprise Associates (NEA), among 146 tracked co-investors.
- What size deals does Pivotal Life Sciences back?
- Across 9 deals with disclosed amounts, Pivotal Life Sciences has joined rounds of $12.5M – $175M (median $80M).
Images
Co-investors · 31
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
SR One Capital Management is a life sciences venture capital firm that takes a 'back-and-build' approach, providing entrepreneurs with human, intellectual, and financial resources. It emerged from the legacy SR One team formerly part of GSK.
Longitude Capital is a venture growth investor in biotechnology, medical technology, and health solutions companies, investing across both private and public companies to improve clinical outcomes and reduce the cost of care.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
▶19 more co-investors
RiverVest Venture PartnersSV AngelEQT Life SciencesSofinnova PartnersJohnson & Johnson Innovation – JJDCThe Column GroupDomain AssociatesSV Health InvestorsInkefBVCFRevolutionMaveronOperator LPboldstart venturesEarlybird Venture CapitalScalar CapitalDimension CapitalOUP (Osage University Partners)JMI Equity
Firms observed investing alongside Pivotal Life Sciences, from public investor directories. Shared companies are the overlap with Pivotal Life Sciences's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.